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Background: Acquired resistance to glucocorticoids
constitutes a major clinical challenge, often overlooked in
the search for improved alternatives to classic steroids.
We sought to unravel how two glucocorticoid receptor-
activating compounds, dexamethasone and Compound A,
influence glucocorticoid receptor levels and how this can
be correlated to their gene regulatory potential.
Methods: Compound A and dexamethasone were
applied in a short-term and long-term treatment protocol.
By quantitative PCR analysis in fibroblast-like synoviocytes
(FLS) the gene regulatory potential of both compounds in
the two experimental conditions was analysed. A parallel
Western blot assay revealed the glucocorticoid receptor
protein levels in both conditions (ex vivo). In addition, this
study examined the effect of systemic administration of
dexamethasone and Compound A, in concentrations
effective to inhibit collagen-induced arthritis, in DBA/1
mice on glucocorticoid receptor levels (in vivo).
Results: Compound A does not induce a homologous
downregulation of glucocorticoid receptor in vivo and ex
vivo, thereby retaining its anti-inflammatory effects after
prolonged treatment in FLS. This is in sharp contrast to
dexamethasone, showing a direct link between prolonged
dexamethasone treatment, decreasing glucocorticoid
receptor levels, and the abolishment of inflammatory gene
repression in FLS. It was also observed that the acquired
low receptor levels after prolonged dexamethasone
treatment are still sufficient to sustain the transactivation
of endogenous glucocorticoid-responsive element-driven
genes in FLS, a mechanism partly held accountable for the
metabolic side-effects.
Conclusion: Compound A is less likely to evoke therapy
resistance, as it does not lead to homologous glucocor-
ticoid receptor downregulation, which is in contrast to
classic glucocorticoids.
Sixty years after the first chemical synthesis of
cortisone, also known as compound E, glucocorti-
coids remain the cornerstone drugs used in treat-
ment protocols of a wide range of inflammatory
and immune disorders.1 However, and although
the first impressions were very positive, it soon
became clear that the frequent and prolonged
administration of glucocorticoids influences a
diverse set of key biological functions and causes
severe, sometimes irreversible, side-effects.2 In this
respect, we have to recognise that, if glucocorti-
coids were to be discovered today, they would
probably face difficulties in order to obtain
regulatory approval. Nevertheless, despite the
ongoing interest and efforts of both the academic
world and the pharmaceutical industry, no other
drug has been able to compete with glucocorticoids
regarding their anti-inflammatory effect, therapeu-
tic benefit, the variety of applications and the
number of patients treated. As such, continued
efforts are made to find and synthesise compounds
with the same anti-inflammatory effects as classic
steroids, yet with reduced side-effects.3
From a molecular point of view, it is hypothe-
sised that the unwanted effects of glucocorticoids
can be separated from their beneficial effects.
Glucocorticoids are small lipophilic molecules that
diffuse freely through the cell membrane to
interact with the glucocorticoid receptor. The
ligand-mediated activation of the glucocorticoid
receptor evokes a conformational change, allowing
the receptor to translocate to the nucleus and to
influence gene expression in a positive (transacti-
vation) and in a negative manner (transrepression).
To exert its transactivation function the glucocor-
ticoid receptor binds to glucocorticoid-responsive
elements (GRE) in the promoter of glucocorticoid-
responsive genes. However, for its transrepression
function the glucocorticoid receptor interferes with
the functionality of other transcription factors, eg,
the pro-inflammatory transcription factor nuclear
factor kappa B (NF-kB).4 5 It is believed that
glucocorticoid receptor modulators that predomi-
nantly induce repression over activation display an
improved safety profile, and the many new patent
applications arising in this field indicate that this
research area continues to be of great interest.3
In this respect, we characterised Compound A, a
stable analogue of the hydroxyphenyl aziridine
precursor found in the Namibian shrub Salsola
tuberculatiformis Botschantzev6 (fig 1) as a selective
glucocorticoid receptor modifier, dissociating glu-
cocorticoid receptor-mediated transrepression from
its transactivation function in vitro.7 The anti-
inflammatory potential of Compound A was
furthermore confirmed in vivo in the zymosan-
induced arthritis model and in the collagen-induced
arthritis (CIA) model, concomitantly in the
absence of the unwanted diabetogenic effects.7 8
However, in addition to the side-effects associated
with prolonged glucocorticoid treatment, it has
been reported that approximately 30% of patients
fail to respond to even high doses of glucocorti-
coids.9 10 Moreover, even though some patients
initially seem to benefit from glucocorticoid
therapy, they can eventually develop resistance.11
Different molecular mechanisms have been
hypothesised to explain the phenomenon of
acquired glucocorticoid resistance. In this context,
it has been proposed that the cellular sensitivity to
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glucocorticoids is directly proportional to the receptor concen-
tration.12–14 Consequently, the downregulation of glucocorticoid
receptor levels observed after ligand treatment,15 which is in se a
protection mechanism to safeguard the cell from continued
signalling in the presence of ligand,12 16 17 may impede their
widespread therapeutic use.
Notwithstanding, this unresponsiveness constitutes a major
therapeutic challenge,11 18 and this aspect is often overlooked in
the search for improved ligands. We thus studied the effect of
prolonged treatment with Compound A and the synthetic
glucocorticoid dexamethasone on the homologous downregula-
tion of the glucocorticoid receptor. In addition, we unravelled
how this homologous downregulation affects the ability of the
glucocorticoid receptor to repress pro-inflammatory cytokine
expression and to induce GRE-driven gene expression. As an ex-
vivo working model, we used a physiologically relevant system
to rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS)
isolated from the inflamed synovium of RA patients.
MATERIAL AND METHODS
Isolation and culture of cells
FLS cells were obtained from patients with active RA, according
to the revised criteria of the American College of
Rheumatology.19 The study was approved by the local ethics
committee. Isolation and culturing of the FLS was performed as
described previously.8
Cytokines and reagents
Recombinant murine TNF was produced in our laboratory.20
Dexamethasone was purchased from Sigma (St Louis, Missouri,
USA). Compound A, 2-(4-acetoxyphenyl)-2-chloro-N-methyl-
ethylammonium chloride was produced and stored as described6
(Alexis Biochemicals, Lausen, Switzerland). Anti-glucocorticoid
receptor (H-300) and anti-p42/p44 (extracellular signal-regulated
kinase; ERK) were purchased from Santa Cruz Biotechnology
(Santa Cruz, California, USA) and from Cell Signalling (Beverly,
Massachusetts, USA), respectively. The human inflammation
antibody array III was purchased from RayBiotech (Norcross,
Georgia, USA) and was probed with cultivation medium of RA
FLS, which had been on the cells for 3 days.
DBA/1 mice
Male 8–12-week-old DBA/1 mice were purchased from Janvier
(LeGenest Saint Isle, France) and housed following institutional
guidelines. All animal procedures were approved by the
institutional animal care and ethics committee. For the
detection of homologous downregulation in vivo, DBA/1 mice
were randomly assigned and were, during a period of 8 days,
treated daily with phosphate-buffered saline (PBS; 200 ml),
dexamethasone (20 mg dissolved in 200 ml PBS) or Compound A
(300 mg dissolved in 200 ml PBS), after which they were killed and
their livers isolated. For the isolation of RNA, as well as the reverse
transcription of messenger RNA from FLS and murine liver tissue,
we refer to the previously described protocol.8 The induction of
CIA in DBA/1 mice is described in Dewint et al.8 The clinical
severity of arthritis paws was graded according to standard
evaluation procedures. For more details refer to Dewint et al.8
Western blot analysis
FLS were seeded in six-well plates and grown to subconfluence
before induction. Total protein was extracted and equal
amounts of protein21 were subjected to Western blotting.22
Quantitative PCR
For the isolation of RNA, as well as the reverse transcription of
mRNA from FLS and murine liver tissue, we refer to the previously
described protocol.8 The complementary DNA obtained was
amplified by a quantitative PCR reaction with iQ Custom SYBR
Green Supermix (Biorad, Hercules, California, USA).
Statistical analysis
All analyses were performed with the commercially available
statistical package GraphPad Prism 4. For normally distributed
continuous data differences between groups were explored by
one-way analysis of variance, followed by a Dunnett’s multiple
comparison test. If Gaussian distribution was not assumed,
statistical significance was determined by means of the Mann–
Whitney test.
RESULTS
We recently reported on the potential of Compound A to
attenuate CIA in DBA/1 mice.8 We here confirm that a clear
anti-inflammatory response can be observed when mice were
administered daily, for a period of 8 days, with Compound A
(300 mg) or dexamethasone (20 mg) in comparison with PBS-
treated animals (fig 2A). The mean clinical severity chart clearly
shows that PBS-treated mice show a significant increase in
clinical severity from the day of onset of arthritis (termed day 1
in fig 2A) to the end of the experiment, 8 days later (termed day
8 in fig 2A). Treatment of the mice with dexamethasone or
Compound A, on the other hand, efficiently inhibits further
progression of arthritis (fig 2A).8 Surprisingly, we noticed that
the concentrations of dexamethasone used had a significant
downregulatory effect on the glucocorticoid receptor concen-
tration levels in DBA/1 mice liver tissue. In sharp contrast,
systemic treatment of the mice with Compound A (300 mg) did
not affect glucocorticoid receptor expression levels in vivo
(fig 2B). Also ex vivo, when FLS derived from patients with RA
were treated with dexamethasone, a fast and significant
reduction in glucocorticoid receptor protein levels could be
observed. The results of a time-kinetics experiment in FLS,
wherein FLS were treated with dexamethasone (1 mM),
Compound A (10 mM) or solvent (EtOH) for 3, 6, 9 or 24 h,
demonstrate that although there is not a significant decline in
glucocorticoid receptor protein levels in FLS after 3 h of
dexamethasone treatment, a clear decrease in receptor concen-
trations can be observed when dexamethasone is added for 6, 9
or 24 h (fig 2C). After treatment of the cells with Compound A,Figure 1 Chemical structure of Compound A.
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such an effect could not be observed at any of the investigated
time points.
We reasoned that this mechanism of homologous down-
regulation may drastically affect the cellular sensitivity of
primary human RA FLS to glucocorticoid therapy. To correlate
the homologous downregulation of glucocorticoid receptor with
the anti-inflammatory potential of both compounds, we
compared the therapeutic potential of both compounds in
two different experimental settings. In the first setup we
pretreated the FLS with solvent, dexamethasone (1 mM) or
Compound A (10 mM) for 1 h, after which TNF was added for
6 h. The anti-inflammatory agents dexamethasone and
Compound A thus resided on the FLS for a timespan of 7 h,
hereby mimicking a short-term treatment protocol.
Alternatively, we pretreated the cells with solvent, dexametha-
sone (1 mM) or Compound A (10 mM) for 24 h, after which
TNF was added for 6 h. Dexamethasone and Compound A were
thus kept on the cells for 30 h, reflecting a prolonged treatment
protocol. Before analysing the results of the short-term and
long-term treatment protocols, we first confirmed the signifi-
cance of the pro-inflammatory mediators IL-6, IL-8 and
macrophage chemoattractant protein 1 (MCP-1)23 24 on the
basis of a human inflammation array and indeed identified these
three markers as the most prominent pro-inflammatory
mediators expressed by RA FLS (fig 3A). We observed that,
when dexamethasone is added to the FLS for a short treatment
protocol, the amounts of glucocorticoid receptor are sufficient
to downregulate the TNF-induced gene expression of MCP-1,
IL-8 and IL-6 efficiently (fig 3B). However, when administered
for a prolonged time to FLS, dexamethasone failed to repress
TNF-induced MCP-1, IL-8 and IL-6 expression (fig 3B). A
parallel Western blot experiment confirmed that, in the
prolonged treatment protocol, the effect of dexamethasone on
the glucocorticoid receptor protein levels became more pro-
nounced than in the short-term treatment protocol, thereby
explaining the abolishment of its anti-inflammatory effect
(fig 3B). Very interestingly, our data show that Compound A
did not reduce the glucocorticoid receptor levels in RA FLS, and
this is reflected by its efficiency in repressing pro-inflammatory
cytokine expression, even on a long-term basis. Indeed, even
after prolonged treatment, Compound A was still able to repress
the expression of IL-6, IL-8 and MCP-1 in FLS efficiently (fig 3B).
As it is well known that glucocorticoids not only influence
gene expression in a negative way, but additionally induce the
expression of GRE-driven genes, we questioned how these lower
glucocorticoid receptor levels influence the transactivation
capacity of the receptor. Our data show that under conditions
in which dexamethasone failed to exert its anti-inflammatory
effects (prolonged treatment protocol), ie, when glucocorticoid
receptor protein levels are low, this glucocorticoid was still able
to induce procollagen C-endopeptidase enhancer 2 (PCOLCE2)
and glutamine synthetase (GS) expression (fig 3C), a late
response gene and an early response gene, respectively. In
parallel with what we found before, Compound A, being a
dissociated glucocorticoid receptor modulator, does not support
the upregulation of GRE-driven genes, exemplified by
PCOLCE28 and GS (fig 3C).
DISCUSSION
In this report, we highlight an intriguing molecular aspect of
glucocorticoid receptor biology, which has to be borne in mind
Figure 2 (A) Daily treatment with Compound A (CpdA; 300 mg) or dexamethasone (DEX; 20 mg) inhibits the further development of collagen-induced
arthritis. Statistical significance was determined with the Mann–Whitney test, two-tailed p value (day 1 vs phosphate-buffered saline (PBS) (day 8)
**p = 0.0019; PBS vs dexamethasone **p = 0.0095; PBS vs Compound A *p = 0.0140). Note that the clinical severity score was 0 for all the animals
treated with dexamethasone. (B) After 8 days of treatment, liver samples were taken from the PBS, dexamethasone (20 mg) or Compound A (300 mg)
treated DBA/1 mice. Quantitative PCR analysis was performed for the detection of glucocorticoid receptor (GR) in the different samples. Gene
expression of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used for normalisation. Statistical significance was
determined with the Mann–Whitney test, two-tailed p value (PBS vs Compound A p = 0.4127 (non-significant, ns); PBS vs dexamethasone
*p = 0.0173). (C) Fibroblast-like synoviocytes were treated with dexamethasone (1 mM), Compound A (10 mM) or solvent (EtOH) for 3, 6, 9 or 24 h as
indicated in the figure. Western blot analysis was performed on total protein extracts with an anti-glucocorticoid receptor antibody. The detection of
extracellular signal-regulated kinase (ERK) was used as a loading control.
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Figure 3 (A) The human inflammation array was incubated with medium of cultured fibroblast-like synoviocytes (FLS) and developed following the
manufacturer’s instruction. (B and C) FLS were pretreated with solvent, dexamethasone (DEX; 1 mM) or Compound A (CpdA; 10 mM) for 1 h (short-
term treatment protocol) or 24 h (prolonged treatment protocol), as indicated in the figures. Afterwards, TNF (2000 units/ml) was added for 6 h.
Expression of the pro-inflammatory mediators macrophage chemoattractant protein 1 (MCP-1), IL-8 and IL-6, as well as of the glucocorticoid-
responsive element-driven genes PCOLCE2 and GS, was monitored by means of quantitative PCR. Gene expression of the housekeeping gene HPRT
was used for normalisation. Statistical significance was determined by one-way analysis of variance (nsp.0.05; *p,0.05; **p,0.01). Dexamethasone
and Compound A-treated samples were compared with the corresponding TNF-induced samples with Dunnett’s multiple comparison test. One
representative experiment is shown and results represent mean (SD) of a triplicate experiment. Western blot analysis was performed in parallel on total
extracts with an anti-glucocorticoid receptor (GR) antibody. The detection of extracellular signal-regulated kinase (ERK) was used as a loading control.
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when developing new, improved glucocorticoid receptor activa-
tors. Although the aspect of homologous downregulation of the
glucocorticoid receptor has already been reported extensively,
even in peripheral blood mononuclear cells of patients with
rheumatic disease,25 a direct link with the anti-inflammatory
potential of these drugs has, to our knowledge, never been
proved. Indeed, different molecular mechanisms have been
linked to the complex phenomenon of glucocorticoid resistance,
including overexpression of the glucocorticoid receptor b
isoform, an altered expression of membrane-bound glucocorti-
coid receptor, activity of the multidrug resistance pump and the
increased activation of inflammatory signalling cascades,
including STAT5, activator protein 1, NF-kB and mitogen-
activated protein kinase.14 Although the negative influence of
NF-kB on glucocorticoid signalling has been linked to a mutual
cross-talk mechanism,13 the detrimental effects of mitogen-
activated protein kinase on glucocorticoid responsiveness have
been attributed to an altered phosphorylation status of the
receptor, which can drastically affect glucocorticoid receptor
ligand binding (reducing the binding affinity or Kd), Hsp90
interactions, subcellular localisation and transactivation poten-
tial of the receptor.14 However, the results presented in this
study show that primary FLS isolated from the inflamed
synovium of arthritis patients are only initially responsive to
the therapeutic effects of dexamethasone, ie, after a short-term
treatment protocol. These results indicate that the unrespon-
siveness of FLS to the anti-inflammatory properties of dex-
amethasone is not an intrinsic property of the cells. When the
cells are treated with this steroid for a prolonged time, on the
other hand, FLS become insensitive to the anti-inflammatory
effect of dexamethasone. In line with this, we noticed that the
acquired resistance to glucocorticoids coincides with a firm
downregulation of glucocorticoid receptor protein levels in FLS.
Previous molecular studies on glucocorticoid receptor homo-
logous downregulation mainly focused on GRE-driven gene
expression, and concluded that the remaining receptors are
competent to respond to hormone, albeit with reduced
efficiencies.17 However, our data reveal a more complex pattern
of gene regulation after prolonged steroid treatment. Evidence is
provided showing that homologous downregulation of gluco-
corticoid receptor in FLS from RA patients has major effects on
the transrepression function of the receptor, in contrast to its
influence on the transactivation function. Notwithstanding
some exceptions, a body of evidence supports the belief that the
transrepression function of the receptor is mainly responsible
for the anti-inflammatory effects, whereas its transactivation
function is held accountable for most of the metabolic side-
effects. Therefore, it is not surprising that some patients, who
slowly develop resistance to the therapeutic effects of gluco-
corticoids, still display many of the unwanted effects associated
with prolonged glucocorticoid treatment.26 By confirming our
data on homologous downregulation after dexamethasone
treatment in vivo in liver tissue of DBA/1 mice, we indicate
that this phenomenon is not restricted to sites of inflammation,
but rather represents a general effect on the organism.
Consequently, these findings open up new avenues for the
development of glucocorticoid receptor modulators, not only
with an improved benefit to the side-effect ratio, but also with
the perspective that ligand-induced resistance may well be
avoidable, an aspect that has often been overlooked in the past.
We provide here proof of principle that such molecules may be
found. Indeed, although it has been stated before that
glucocorticoid receptor modulators that induce glucocorticoid
receptor activation and subsequent nuclear translocation all
induce a homologous downregulation of the receptor,15 we here
show that the glucocorticoid receptor-activating Compound A,7
which induces nuclear translocation of the receptor in FLS,8 does
not evoke ligand-induced downregulation in the ex-vivo patient
material. The molecular basis for the differences in glucocorti-
coid receptor gene regulation after dexamethasone and
Compound A treatment is not yet clear, but various hypotheses
can be put forward. First, it is possible that Compound A elicits
a different conformational change of the receptor compared
with dexamethasone,7 which is not recognised by the ubiqui-
tination machinery. Alternatively, it is known that phosphor-
ylation is a positive signal for degradation.27 In this respect, it is
interesting to note that differences in the phosphorylation
status of glucocorticoid receptors can be observed after the
treatment of lung carcinoma cells with Compound A versus
dexamethasone.7 Note that the above hypotheses reflect post-
translational mechanisms to regulate the levels of glucocorticoid
receptor protein. However, in DBA/1 mice a decrease in receptor
levels could already be observed at the mRNA level, implying
that the glucocorticoid receptor promoter and its accessory
proteins can differentiate between dexamethasone and
Compound A-activated glucocorticoid receptor. In conclusion,
it is possible that the higher levels of glucocorticoid receptor
protein observed after Compound A treatment compared with
dexamethasone treatment reflect a combination of molecular
events occurring at different levels of gene and protein
regulation. Nonetheless, we hypothesised and confirmed that
Compound A, in contrast to dexamethasone, retains its anti-
inflammatory potential even after prolonged treatment, a
finding with significant therapeutic interest for many chronic
inflammatory diseases in need of long-term immunosuppression
therapies.
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